Business
Roadman Investments Closes Acquisition of CLOV Biopharma Corp.
(via TheNewswire) March 10 , 2020 - TheNewswire - VANCOUVER, British Columbia...
About this update from Futuregen Industries Corp.
[{"type":"text","content":"Roadman Investments Closes Acquisition of CLOV Biopharma Corp.(via TheNewswire)\n \n \nMarch 10, 2020 - TheNewswire - VANCOUVER, British Columbia - Roadman Investments Corp. (TSXV:LITT)(FWB:1QD)(OTC:RMANF) (\"Roadman Investments\" or the \"Company\") is pleased to announce that it has received final acceptance from the TSX Venture Exchange and has now closed its previously contemplated Definitive Agreement (the \"Agreement\") whereby it has acquired all of the issued and outstanding shares of CLOV Biopharma Corp. (\"CBP\"). \n\n \n \nCLOV Biopharma Corp. is focused on conducting further research and development of cedar leaf oil vapour (\"CLOV\") for the purposes of preventing the spread of Coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial viruses. CBP is working in partnership with Dr. James Hudson, Ph.D, who is widely considered to be one of the foremost virologists in Canada, in an effort to expand upon and potentially commercialize his many years of study and scientific analysis involving the antimicrobial and antiviral properties of cedar leaf (Thuja plicata) oil. Previous studies by Dr. Hudson have shown that most of the human respiratory viruses tested so far have been found vulnerable to cedar leaf oil and cedar leaf oil vapour. It is expected that corona viruses, including COVID-19, will be similarly vulnerable. In general, the respiratory viruses not only can kill susceptible cells and multiply and spread, but they can also induce the production of excessive amounts of inflammatory cytokines, which can result in chronic inflammation of the lungs, as in bronchitis. Previous tests have shown that cedar leaf oil can inhibit this process in a model cell culture system. \n\n \n \nPreviously published manuscripts authored by Dr. Hudson have concluded that, in a laboratory setting, CLOV was effective in killing (inactivating) several human respiratory viruses, including Influenza virus, Rhinovirus, Adenovirus, as well as Herpes simplex virus. It was also shown that short-term exposure to CLOV had no adverse effect on cultured lung epithelial cells, thus confirming it is not cytotoxic. Further, it was shown that CLOV also partly reversed the pro-inflammatory effect caused by Rhinovirus infection, which means that it acts as a m...